VYNE Therapeutics (VYNE) Leases (2019 - 2025)
VYNE Therapeutics (VYNE) has disclosed Leases for 6 consecutive years, with $32000.0 as the latest value for Q2 2025.
- For the quarter ending Q2 2025, Leases fell 78.81% year-over-year to $32000.0, compared with a TTM value of $32000.0 through Jun 2025, down 78.81%, and an annual FY2024 reading of $93000.0, down 55.07% over the prior year.
- Leases was $32000.0 for Q2 2025 at VYNE Therapeutics, down from $62000.0 in the prior quarter.
- Across five years, Leases topped out at $1.4 million in Q1 2021 and bottomed at $32000.0 in Q2 2025.
- Average Leases over 4 years is $451500.0, with a median of $165500.0 recorded in 2024.
- The sharpest move saw Leases fell 18.25% in 2021, then crashed 78.81% in 2025.
- Year by year, Leases stood at $1.0 million in 2021, then crashed by 80.02% to $207000.0 in 2023, then tumbled by 55.07% to $93000.0 in 2024, then crashed by 65.59% to $32000.0 in 2025.
- Business Quant data shows Leases for VYNE at $32000.0 in Q2 2025, $62000.0 in Q1 2025, and $93000.0 in Q4 2024.